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Abstract
Introduction: Global Initiative for Asthma (GINA) reports emphasize the use of validated and simple tools in order to assess the 
level of asthma control, as the Asthma Control Test (ACT). However, an ACT does not include assessment of airway inflammation, 
which is better reflected when measuring nonspecific bronchial hyperresponsiveness (BHR). The authors aimed to find out if the 
level of asthma control quantified by an ACT correlates with BHR and pulmonary function tests. 
Material and methods: 118 asthmatics participated in the study. All patients completed an ACT. The scores of the ACTs were 
compared with pulmonary function tests and BHR assessed with the methacholine challenge test and expressed as a provocative 
concentration of methacholine, inducing a 20% decline in the FEV1 (PC20 M in mg/ml).
Results: Patients with controlled asthma amounted to 52 (44%) while those with uncontrolled asthma amounted to 66 (56%). 
In patients with controlled asthma (ACT score ≥ 20) the mean geometric value of PC20M was 2.72 mg/ml (range from 0.25 to 
> 8.0), whereas 0.94 mg/ml (range from 0.28 to 8.0) (p = 0.02) was observed in patients with uncontrolled asthma (ACT score 
< 20). Almost 64% (21/33) of uncontrolled asthmatics achieved normal lung function (FEV1 > 80% pred. value) while 19% (5/26) 
patients with controlled asthma presented an FEV1 < 80% predicted value. Asthma duration in years in controlled asthmatics was 
significantly shorter than in uncontrolled patients (6.2 ± 8.9 vs. 12.0 ± 11.4, p = 0.005)
Conclusion: In determining the most accurate level of asthma control it is reasonable to use an ACT in conjunction with BHR, 
which provides more accurate assessment of bronchial inflammation than ventilatory parameters alone.
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Introduction
Recent GINA (Global Initiative for Asthma) 
guidelines recommend treating asthmatic patients 
towards assessing asthma control [1, 2]. The as-
sessment of asthma control during a short period 
of time reflects the real nature of this chronic dis-
ease [1]. Control determines the degree to which 
the manifestations of asthma are minimized and, 
due to the multidimensional pathogenesis of the 
disease, it should refer not only to clinical man-
ifestations but also to laboratory biomarkers of 
inflammation and pathophysiological features of 
the disease. According to the GINA report 2014, 
an assessment of asthma control as well as the 
effects of asthma treatment should be based on the 
evaluation of daytime and nocturnal symptoms, 
the limitation of physical activities and the use of 
rescue medication [3]. In practice GINA reports 
recommend the use of validated and simple tools 
in order to quantify the level of asthma control as 
with the Asthma Control Test (ACT), which pro-
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vides a numerical value for control obtained by 
summing together responses for the 5 above-men-
tioned items [4]. However, ACT does not include 
an assessment of airway inflammation, this being 
the main pathogenic mechanism of asthma. This 
indicates that the use of an ACT alone cannot 
provide sufficient objective asthma control and 
may lead to an inappropriate clinical decision. 
Studies have shown that asthmatic patients with 
an adequate control of their symptoms might be 
still at risk of severe exacerbations associated 
with underlying airway inflammation [5]. As 
inflammation contributes to bronchial hyperrs-
esponsiveness, BHR is used to monitor asthma 
treatment [6−8]. It is also well-known that BHR 
is weakly associated with asthma symptoms, 
the need for medications and lung function [8]. 
However, there is no evidence confirming the re-
lationship between BHR and nonspecific stimuli 
and the total ACT score. Due to the asthma control 
approach regarding asthma management, it was 
of interest to find if the level of asthma control 
assessing presented in an ACT correlates with the 
BHR and pulmonary function test. 
Material and methods
A total of 118 asthma patients, 84 women and 
34 men, with a mean (± SD) age of 44 ± 15 years 
(range 18−75 years) participated in this study. 
The subjects were recruited from the Medical Uni-
versity Out-patient Asthma Clinic in Lodz. The 
mean asthma duration was 10 ± 11 with a range 
from 3 to 43 years. As for all patients, the diag-
nosis of current asthma was made by a specialist 
and consistent with the GINA 2006 guideline [1]. 
All participants were interviewed regarding the 
use of antiasthmatic medications. Inhaled cortico-
steroids (ICSs) and long-acting b2-agonists (LABA) 
combinations were the most common medication 
regimen used by approximately 60% of patients, 
either in a  single inhaler or as two separate 
components. Twenty-four per cent (28/118) of 
subjects were treated with LABA and a low dose 
of ICSs (beclomethasone dipriopionate — BDP < 
500 µg, budesonide ≤ 400 µg, ciclesonide ≤ 160 
µg, fluticasone ≤ 250 µg). Twenty-nine per cent 
(34/118) of them were administered LABA with 
a medium ICS dose (BDP 500−1000 µg, budesonide 
400−800 µg, ciclesonide 160−320 µg, fluticasone 
250−500 µg). Eight per cent (10/118) of patients 
took separately ICSs in a dose exceeding 1000 µg 
of BDP, 800 µg budesonide, 320 µg ciclesonide 
and 500 µg fluticasone respectively. Furthermore, 
15% of subjects used systemic corticosteroids in 
a daily dose equivalent to 5−10 mg prednisone, 
in addition of other controller medications, 
while the remaining 5 participants required no 
antiasthmatic treatment at the moment of being 
included into the study. Pulmonary function tests 
(PFTs) were performed according to the American 
Thoracic Society (ATS)/European Respiratory So-
ciety (ERS) consensus criteria of acceptability and 
reproducibility, using a volumetric storage spi-
rometer (Vitalograph 2160, Vitalograph Ltd.) [9]. 
The forced expiratory volume in the first sec-
ond (FEV1) and forced vital capacity (FVC) were 
measured using a calibrated spirometer. Subjects 
were required to have abstained from using LABA 
for at least 48 hours and short-acting b2-agonists 
(SABA) for 6 hours prior to tests. The best of 
three reproducible measurements for FEV1 and 
FVC were recorded and expressed as a percent-
age of the predicted value [9]. In order to avoid 
any risk of serious adverse events of bronchial 
provocation, only subjects with stable asthma 
(N = 59; 26 patients with controlled asthma and 
33 with uncontrolled asthma) and with a baseline 
of FEV1 ≥ 50% of that predicted and/or ≥ 1litre 
were included into the study. Nonspecific bron-
chial hyperresponsiveness (BHR) was assessed 
by the methacholine challenge test that was 
performed using a DeVilbiss nebulizer with an 
output of 0.26 ml/min and an air flow of 6 l/min, 
according to the method described previously by 
Cockcroft et al. [10] with some personal modifi-
cations. Subjects inhaled methacholine chloride 
(by Merck) via a mouthpiece wearing a nose clip 
in doubling concentrations from 0.015 mg/ml to 
16 mg/ml for 2 minutes every 5 minutes. FEV1 was 
recorded at 30 and 90 seconds after each inhala-
tion. Bronchial responsiveness was expressed as 
the provocative concentration of methacholine 
that induces a 20% decline in the FEV1 from base-
line (PC20). The PC20M was calculated by a linear 
interpolation from a dose-response curve between 
two points closest to a 20% fall of FEV1. A positive 
response for methacholine was considered when 
at a value of PC20 ≤ 8 mg/ml. BHR with a PC20 
value ≤ 8 mg/ml and > 1 mg/ml was defined as 
mild, a value of PC20 ≤ 1 m/ml and > 0.25 mg/ml 
as moderate, and as severe when a PC20 value was 
equal to or lower than 0.25 mg/ml.
The level of asthma control was measured 
using the Asthma Control Test (ACT), which was 
completed by each patient [4]. An ACT covers 
5 items assessing limitations related to asthma 
on daily functions (question 1), the frequency 
of breathlessness (question 2), the presence of 
nocturnal awaking (question 3), the use of rescue 
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(n = 26) (n = 33)
2.72* 0.94*
N % N %
0–0.25 4 15% 10 30%
0.26–1 9 35% 14 43%
> 1–8 11 42% 9 27%
> 8 2 8% 0 0%
(PC20M — provocative concentration of methacholine that induces a 20% decline in the FEV1 from baseline); *XgPC20M mg/ml, p = 0.02
medication (question 4) and the evaluation of 
the patient’s subjective perception of their level 
of asthma control (question 5) over the previous 
4 weeks. Each question included 5 response 
options from one to five with an increasing level 
of asthma control. A total score was obtained by 
summing up responses for 5 items ranging from 5 
to 25 points. Three levels of asthma control were 
identified: scores from 5 to 19 indicated uncon-
trolled asthma, scores from 20 to 24 indicated 
well-controlled asthma while a score of 25 indicat-
ed total control. All participants were additionally 
requested to answer the following question: “Do 
you adhere to the treatment prescribed by the 
physician?” The answer was only yes or no.
The study was carried out after approval of 
the Ethics Committee of the Medical University 
in Lodz. Prior to enrollment each subject provided 
written informed consent. 
The summary of statistics includes median 
(min-max) values, mean ± standard deviation 
values and geometric mean values. The relation-
ship between the hyperresponsiveness to metha-
choline, lung function and the ACT values were 
calculated using Pearson’s correlation coefficient 
for continuous variables. An c2 analysis was used 
for comparison of the distribution of categorical 
variables. A value of p < 0.05 was considered 
statistically significant. 
Results
According to the ACT, 56% of patients 
(66/118) were uncontrolled. The similar propor-
tion of females and males with ACT score between 
5 and 19 was seen and it was 55% (46/84) and 
59% (20/34) respectively. Asthma was considered 
well-controlled in 36% (21/59) of subjects. Only 
8% (10/118) of all participants reported total 
control during the last 4 weeks. Further analyses 
were performed considering two populations: 
controlled (ACT score ≥ 20) and uncontrolled 
(ACT score < 20). Of the patients with controlled 
asthma (N = 26) the geometric mean value of PC20 
was 2.72 mg/ml and only 0.94 mg/ml in patients 
with uncontrolled asthma (N = 33) (Table 1). The 
mean geometric values of PC20M in controlled and 
uncontrolled patients were significant different (p 
= 0.02). Half of the patients with an ACT score ≥ 
20 points had moderate or severe BHR with PC20M 
≤ 1 mg/ml (Table 1). 
Although there was a  tendency towards 
a relationship between the fifth response on each 
question in the ACT and the PC20M, a significant 
correlation was found only regarding the second 
(R = 0.498; p < 0.001) and fourth questions (R 
= 0.27; p < 0.05). A higher response option to 
questions 2 and 4 was correlated with a higher 
mean value of PC20M (Fig. 1). The estimation of 
dependence between FEV1 values and ACT scores 
revealed that patients with an ACT score less or 
equal to 19 points had a significantly lower mean 
FEV1 (85.7% ± 18%) compared to those with total 
and well-controlled asthma (96.1% pred. value 
± 13.6%), (p = 0.017). At the same time, despite 
the significantly lower frequency of FEV1 value 
over 100% of predicted, almost 64% (21/33) of 
uncontrolled asthmatics achieved normal lung 
function (FEV1 > 80%) (Table 2).
An evaluation of the influence of various an-
alysed factors, including demographics on asthma 
control assessed by an ACT, did not identify any 
significant correlations. Adherence to treatment 
did not contribute to better ACT scores because 
the majority of controlled patients (85% — 22/26), 
as well as those uncontrolled (94% — 31/33) 
reported taking prescribed medications on 
a  regular basis. Moreover, co-occurring rhini-
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Figure 2. Relationship between Xg PC20M in mg/ml and asthma treatment; ICS L — low dose of ICS; ICS H — high dose of ICS; ICS M — medium 
dose of ICS; Oral CS — oral corticosteroids; SABA — short-acting beta-agonists; LABA — long-acting beta-agonists





(n = 26) (n = 33)
96.1 (± 13.6)* 85.7 (± 18)*
N % N %
≥ 100 14 54% 8 24%
80−100 7 27% 13 40%
< 80 5 19% 12 36%
*FEV1 in% pred. value (± SD), p = 0.017
tis and allergic sensitization were not related 
with poorer asthma control. Similarly, despite 
the fact that active smoking was more often 
observed in patients with uncontrolled asthma 
(12% — 4/33 vs. 4% — 1/26), current smoking 
did not significantly deteriorate one’s  control 
of asthma. Furthermore, the above-mentioned 
schemes of asthma treatment do not have a sig-
nificant influence on the ACT score. In addition, 
no association was found between following 
any treatment regimen and the mean values of 
PC20M (Fig. 2) and FEV1 values in patients with 
Figure 1. Relationship between choosing variant of answer regarding ACT and bronchial hyperresponsivenes
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or without asthma control (Fig. 3). Patients who 
did not require current antiasthmatic treatment 
but were well controlled had the lowest BHR 
(PC20M = 6.29 mg/ml) while those with uncon-
trolled asthma had the highest BHR (PC20M = 
0.01 mg/ml).
Taking into consideration asthma duration, 
we demonstrated that the mean duration of the 
disease was significantly shorter in patients 
with an ACT score ≥ 20 compared to those with 
uncontrolled asthma (6.2 ± 8.9 years and 12.2 ± 
11.4 years respectively; p < 0.001). Irrespective of 
asthma duration, in both groups FEV1 were over 
80% of predictive value except for patients with 
a lack of asthma control and those with a ten to 
twenty-year history of disease, when FEV1 was 
75.4% of the normal value (Table 3). Subjects 
who were treated for asthma from 1 to 10 years 
had a significantly higher mean value of PC20M 
when compared to the group with longer duration 
of asthma symptoms (4.75 mg/ml vs 1.28 mg/ml; 
p < 0.05). In a group of uncontrolled patients 
PC20M values behaved similarly. The highest BHR 
was found in subjects with uncontrolled asthma 
and over a twenty-year history of asthma than in 
controlled patients (PC20M = 0.59 mg/ml vs 1.65 
mg/ml; p < 0.05).
Disscussion
An accurate level of asthma control is funda-
mental for the initiation or modification of asthma 
pharmacotherapy. Currently, several parameters 
have been developed to quantify asthma control. 
The ideal measure of asthma control should 
reflect the multidimensionality of asthma, be 
easily interpreted, convenient to perform, quickly 
administered in clinical practice, responsive to 
changes in clinical status, valid and provide re-
liable assessment of asthma control [11, 12]. The 
ACT proposed by Nathan et al. [4], which was 
used in our study, has been developed to meet 
Table 3. Asthma duration, FEV1 in% pred. value and PC20M in mg/ml in patients with controlled and uncontrolled asthma
Asthma
Controlled Uncontrolled
Asthma duration  
(in years)
(n = 26) (n = 33)
6.2 (± 8.9)* 12.2 (± 11.4)*
FEV1** PC20M*** FEV1** PC20M***
≤ 1 99.2 (± 11.9) 1.7 85.8 (± 11) 0.7
> 1−10 91.3 (± 16.3) 4.75 91.4 (± 18.6) 1.28
> 10−20 101.2 (± 1.5) 1.41 75.4 (± 19.2) 0.62
> 20 94.4 (± 19.6) 1.65 82.8 (± 15.4) 0.59
*asthma duration in years, p = 0.005; **FEV1 in% predicted value (± SD); ***XgPC20M in mg/ml
Figure 3. Relationship between FEV1 (% pred.value) and asthma treatment; ICS L — low dose of ICS; ICS H — high dose of ICS; ICS M — medium 
dose of ICS; Oral CS — oral corticosteroids; SABA — short-acting beta-agonists; LABA — long-acting beta agonists
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these needs. Moreover, as the ACT scores were 
responsive to current asthma clinical status, it is 
a suitable survey to drive therapeutic decision 
making (step-up or step-down). A score of 19 on 
the ACT was considered as the best cut-off-point, 
at which the sensitivity and specificity of the 
ACT, whereas the point for classifying patients as 
poorly controlled or well-controlled was 71.3% 
and 70.8% respectively. The ACT proved to be 
a reliable instrument due to the presence of a si-
gnificant correlation with FEV1 values and the 
Asthma Control Questionnaire (ACQ) [13]. Ho-
wever, Stempel et al. [14] demonstrated that the 
combination of both ACT and FEV1 values would 
better determine the patient asthma control than 
either of them alone. Therefore, in our study the 
level of asthma control assessed by a subjective 
numeric tool (ACT) was compared to the pul-
monary function test and measurement of BHR. 
In the light of the above, we found significant 
differences in mean FEV1 values across patients 
with uncontrolled and controlled asthma despite 
the level of mean FEV1 indicating rather normal 
lung function and good asthma control in both 
groups of patients. Even more, a FEV1 value less 
than 80% of that predicted, as one of the criteria 
of poor asthma control, was similarly frequent in 
patients with an ACT score ≥ 20 points, as well as 
in those with the ACT score < 20 points. It should 
be underlined that almost 20% of controlled sub-
jects had FEV1 less than 80% but 64% of patients 
with uncontrolled asthma had FEV1 value within 
the normal range (i.e. FEV1 ≥ 80% predicted). This 
observation suggests that spirometry, which is an 
objective measurement of asthma control, does 
not confirm the ACT scores and consequently 
does not support the multidimensionality and 
the reliability of this test. These findings are con-
sistent with previous studies that have revealed 
a weak correlation between pulmonary function 
and the level of asthma control [14]. It has also 
been shown that patients with intermittent and 
mild asthma have normal lung functioning, ma-
king spirometry less useful in accurate asthma 
control assessment. Moreover, subjective impro-
vement in asthma symptoms may occur without 
any changes of airflow obstruction. Indeed, as 
others have previously reported, continuous FEV1 
measurements cannot be used as a marker for 
potential asthma exacerbations and cannot alone 
predict the loss of asthma control [15]. 
In order to provide a more comprehensive 
view of the overall level of asthma control it seems 
to be sensible to use composite measurements 
comprising different endpoints. Currently, there is 
no clear statement which parameter or its combi-
nation can be considered as the most relevant tool 
to evaluate asthma control. The ACT refers to cli-
nical parameters (daily symptoms, nocturnal awa-
king, need for rescue medication, frequency of bre-
athlessness), which are based on a patient’s self- 
-perception of symptoms. Although the assessment 
of symptoms is undoubtedly important, studies 
indicate that symptoms perception by asthmatic 
patients is often inaccurate, causing problems with 
its interpretation in clinical practice. Even more, 
the perception of dyspnoea intensity varies greatly 
among patients with asthma and therefore may not 
reflect the actual clinical status [16, 17]. Additio-
nally, the ACT does not include an assessment of 
underlying airway inflammation which might be 
better reflected by the measuring of BHR. 
Previous studies have shown that the thre-
shold value of histamine appears to be a more 
sensitive determinant of airway responsiveness 
than changes in FEV1 values after allergen expo-
sure [18, 19]. Moreover, it was found that both in 
seasonal or persistent asthma BHR may be present 
even though FEV1 was within normal range [20]. 
BHR correlates with markers of persistent in-
flammation including sputum eosinophilia and/
or exhaled nitric oxide (eNO) [21]. Sont et al. [22] 
documented that patients treated with inhaled 
corticosteroids (ICSs) guided by the degree of 
BHR, had a  lower exacerbation rate, improved 
lung function and reduced remodeling, com-
pared to those treated based only on asthma 
management guidelines. Linked to this fact, 
BHR normalizing may be important in order to 
improve asthma control. In this study we demon-
strated the lack of association between the level 
of asthma control as assessed by the ACT and the 
degree of BHR. In a group of controlled asthma 
patients, approximately half had severe or mode-
rate BHR while only 2 subjects achieved PC20M 
values exceeding 8mg/ml, which is regarded as 
normal airway responsiveness. Furthermore, the 
significant difference between the geometric 
mean of PC20M in controlled and uncontrolled 
patients observed in our study weakens seriously 
the usefulness of the ACT as a  tool providing 
sufficient information about asthma control. 
These data do not support the multidimensio-
nality of the ACT, but suggest that BHR may 
occur irrespective of the clinical level of asthma 
control. With regard to these, we conclude that 
a total ACT score and BHR measurement do not 
gauge the same aspect of asthma. Thus, an ACT 
without an assessment of BHR, which reflects 
and provides additional information about di-
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sease activity and the risk of exacerbation, may 
lead one to establish an inappropriate level of 
asthma control. Our results confirm the fin-
dings of Bora et al. [23] who demonstrated that 
although ACT can be used in clinical practice, 
it does not correlate with airway inflammation. 
Similarly Melosini et al. [24] found that although 
an ACT can be a valid tool to assess the current 
level of asthma control in terms of symptoms, 
rescue medication use, and PEF variability, in 
cases of pulmonary function and biomarkers 
of airway inflammation they are not related to 
the clinical asthma control. BHR is improving 
with treatment in the long-term, in contrast 
with achieving control of lung function and 
symptoms. Earlier Lündback et al. [25] showed 
that asthma control improvement demonstrated 
as BHR reduction is achievable with adequate 
anti-inflammatory pharmacotherapy. Decreasing 
BHR with treatment requires months or even 
years, while symptoms and lung function have 
been shown to improve relatively quickly. In 
our study, normalizing of BHR was not associa-
ted with longer asthma duration and the use of 
asthma medication. We found that with incre-
asing years of asthma duration patients were 
scored lower on the ACT. Moreover, a  longer 
asthma duration in patients with uncontrolled 
asthma was not related to greater BHR and with 
no meaningful changes in FEV1 values. In accor-
dance with these observations, we could suggest 
that BHR is a more sensitive marker in asthma 
control assessment than FEV1. In addition, our 
results indicated that asthma treatment had no 
significant influence on BHR level and achieving 
optimal asthma control. A combination of ICSs 
and long-acting b2-agonists (LABAs) was used 
by the majority of patients from both groups: 
controlled and uncontrolled. However, several 
studies have shown that ICSs reduce airway 
inflammation and persistent treatment with 
ICSs ameliorates BHR [22, 25]. Bateman et al. 
[26] proved that addition LABA to ICSs provi-
des obtaining clinical control in more patients, 
immediately and at lower doses of ICSs than the 
application of ICSs alone. Our data revealed no 
agreement with these findings and suggest that 
the most effective therapy reflected by ACT sco-
res ranged from 20 to 25 and that the lowest BHR 
value was assured by taking oral corticosteroids 
as an additional asthma treatment. In this case, 
following guidelines to achieve asthma control 
step-down therapy should be reconsidered. The 
highest value of PC20M was observed in control-
led patients but those not having been treated by 
any asthma medication. Even more, patients with 
poor asthma control who had not been treated 
with antiasthmatic medications had the severest 
BHR. On the basis of mean FEV1 results we could 
not reach similar conclusions as the FEV1 values 
obtained in both groups did not identify what 
kind of medications may improve or worsen asth-
ma control. In line with the above, determining 
the most accurate level of asthma control and 
obtaining the more objective ACT scores, it seems 
reasonably to use an ACT in conjunction with an 
assessment of BHR instead of spirometry parame-
ters. Moreover, lung function tests alone should 
not be recommended in the evaluation of asthma 
control and decision making regarding optimal 
pharmacotherapy without including measures 
of the extent of airway inflammation or BHR 
since, lung function tests, as well as symptoms, 
might provide a different assessment, one not the 
reflecting inflammatory process which characteri-
zes asthma. Laprice et al. [27] found that airway 
inflammation and remodeling are more intense 
in more symptomatic patients. Our study showed 
that more symptomatic patients expressed in 
a numerical ACT score also had a lower PC20M 
value that corresponded with moderate to severe 
BHR. In contrast, lower BHR significantly corre-
lated with less intensified breathlessness and the 
infrequent use of rescue medication. 
These observations are consistent with pre-
vious findings indicating that in real-life assess-
ments of asthma control, by means of an ACT 
incorporating a measurement of BHR, allow one 
to obtain the proper level of asthma control and, 
in particular, can provide the relevant information 
for treatment decisions.
The current study shows the possibility 
of inadequate assessment of asthma control as 
evaluated by an ACT. Inadequate suppression 
of airway inflammation follows when its extent 
in guiding anti-inflammatory medications is not 
considered. Unfortunately, despite of the availa-
bility of highly effective pharmacotherapy, this 
problem occurs extensively. The ACT scores 
distinguishing uncontrolled patients from those 
with asthma control seem to be uncertain. Asthma 
control in an ACT is assessed on the basis of sub-
jective intensity of symptoms, limitation in daily 
activity or the need for rescue medication. This 
generally results in overestimating the level of 
control because of poor recognition of symptoms, 
treating them as unavoidable consequences of 
disease [28]. Boulet et al. [29] demonstrated that 
two thirds of patients with mildly and moderately 
uncontrolled asthma, as measured according to 
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asthma guidelines, reported proper control. Fur-
thermore, patients might not realize that there is 
a possibility of improving their quality of life by 
suitable pharmacotherapy. Although the adheren-
ce to prescribed medications is vital to achieve 
therapeutic success in asthma, other determi-
nants may also impact on disease control. This is 
consistent with our observation, which indicated 
that even though almost all patients were in com-
pliance with the prescribed treatment, 56% re-
ported uncontrolled asthma. For effective asthma 
management, GINA reports have recommended 
developing a partnership between the physician 
and the patient, especially in the case of asthma 
as a condition which demands continuous moni-
toring over long period of time and, if necessary, 
individually adjusting one’s treatment. Recently, 
the importance of education in asthma, ensuring 
essential knowledge about recognizing worsening 
asthma control and skills in the proper use or 
modification of medication, has been highlighted. 
According to the INSPIRE (International Asthma 
Patient Insight Research) study only 29% of pa-
tients with asthma are instructed how to increase 
their ICS dose in case of crisis or exacerbation 
while 88% reported a willingness to acquire simi-
lar knowledge [30]. More surprising results were 
presented by the GAPP (Global Asthma Physician 
and Patient Survey) project that showed a huge 
disproportion between the patient’s and physi-
cian’s awareness of implementing education being 
crucial in the self-management of asthma [31]. 
To avoid therapeutic failure of asthma treatment 
and to improve the anti-inflammatory effect of 
ICSs, training in the right technique for inhaler 
device usage should be an integral part of every 
visit [1, 2, 32]. Studies have demonstrated that 
approximately 50% of patients admit not having 
sufficient ability to use their inhaler device [32]. 
Indeed, almost 30% misuse their pressured mete-
red-dose inhalers (pMDI), a phenomenon which 
is due to poor coordination between inhaler 
activation and inspiration [33]. The results of 
this study demonstrate that half of patients with 
controlled asthma had severe or moderate BHR. 
The single use of an ACT does not provide a full 
picture of asthma control because the total ACT 
score and BHR measurements do not measure the 
same aspect of asthma. BHR is a more sensitive 
marker in asthma control assessment than FEV1. 
Therefore, better solution is to combine the objec-
tive parameters assessing asthma control. Thus, 
a BHR measurement which reflects underlying 
disease activity, should be combined with sub-
jective parameters such as an ACT.
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